



Effects of N-alkyl quaternary quinuclidines on oxidative stress biomarkers in SH-SY5Y cells

Antonio Zandona, Lucija Marcelić, Suzana Žunec, Josip Madunić, and Maja Katalinić

Institute for Medical Research and Occupational Health, Division of Toxicology, Zagreb, Croatia

[Received in June 2025; Similarity Check in June 2025; Accepted in July 2025]

Having a broad spectrum of biological and pharmacological activities, including anticholinergic, antihistaminic, antiparasitic, antioxidant, and antitumour, quinuclidine derivatives have piqued much interest in the field of drug discovery and biomedical research. This study investigates the oxidative stress effects of six N-alkyl quaternary quinuclidine derivatives, namely three oximes (QNOH-C_{12,14,16}) and three alcohols (QOH-C_{12,14,16}) in SH-SY5Y neuroblastoma cells to evaluate their safety profile as potential therapeutics. We treated SH-SY5Y cells with their lowest-observed-adverse-effect levels (LOAEL) for 4 h and measured reactive oxygen/nitrogen species (ROS/RNS), lipid peroxidation, glutathione (GSH), superoxide dismutase (SOD) activity, and DNA damage. Q(N)OHs significantly increased ROS and RNS levels, particularly the QNOHs, while lipid peroxidation remained unaffected, and GSH depletion was minimal. Cytosolic Cu/Zn-SOD activity increased significantly with longer alkyl chain substituents, while Mn-SOD activity decreased, indicating mitochondrial damage. DNA damage was not elevated. The observed effects of the tested quinuclidine derivatives appear to depend on their structural properties, as compounds containing hydroxyl groups and shorter alkyl chains had a lower impact. Furthermore, even non-cytotoxic doses of the tested compounds affected cell homeostasis, which underlines the importance of such testing early in the evaluation of new potential drugs.

KEY WORDS: DNA damage; glutathione; mitochondrial dysfunction; oximes; reactive nitrogen species; reactive oxygen species; superoxide dismutase

Quinuclidinium compounds are a diverse class of natural or synthetic chemical agents with a wide range of potential applications in medicine and industry (1–6). These compounds are characterised by a rigid bicyclic core (7) that allows specificity, adaptability, and unique electrostatic properties in various chemical interactions, which makes them ideal candidates for binding to biological targets (8, 9). Recent advances in organic synthesis have enabled the development of synthetic quinuclidinium compounds that enhance the properties of their natural analogues with improved potency, stability, and selectivity for specific biological targets, such as receptors and enzymes, including cholinesterases (4, 10–14). From the therapeutic viewpoint, inhibition of acetyl- and butyrylcholinesterase can increase acetylcholine levels and thus improve cognitive function impaired by neurodegenerative diseases (15).

Several quinuclidinium compounds have shown potent cholinesterase inhibition, but also adverse effects like cytotoxicity. One of the intriguing aspects of quinuclidinium compound activity is biological response to the increase in aliphatic side chain length, as it can enhance the binding efficiency and/or cytotoxicity of quinuclidinium compounds (2–4, 14, 16). Better understanding of the relationship between the side chain length and biological activity may reveal structural factors that contribute to the therapeutic efficacy and safety of these compounds. Therefore, we focused on six quinuclidinium analogues of different side chain lengths,

previously shown to be cytotoxic, to relate their oxidative effects to their structural properties in a SH-SY5Y cell model.

MATERIALS AND METHODS

Chemicals and cell culture

The six tested N-alkyl quaternary quinuclidine compounds (Q(N)OH-C_{12,14,16}) were designed and synthesised by the Professor Ines Primožić group at the University of Zagreb Faculty of Science, Department of Chemistry (Zagreb, Croatia) as described elsewhere (4, 14). Q(N)OHs were prepared as 100 mmol/L stock solutions in dimethyl sulfoxide (DMSO) and diluted to a designated concentration in unsupplemented cell medium prior to experimentation. The selected concentrations correspond to the lowest observed adverse effect level (LOAEL), that is, the concentration achieving 20 % growth inhibition (IC₂₀) at 4 h of exposure, determined in our previous study (14), as follows: 60 µmol/L for QOH-C₁₂, 6 µmol/L for QOH-C₁₄ and QOH-C₁₆, 100 µmol/L for QNOH-C₁₂, 25 µmol/L for QNOH-C₁₄, and QNOH-C₁₆.

The cell line used in the experiments was human neuroblastoma SH-SY5Y obtained from the European Collection of Authenticated

Cell Cultures (ECACC, Salisbury, UK; Cat. No. 94030304). Cells were cultivated in Dulbecco's Modified Eagle Medium (DMEM) F12 with 15 % foetal bovine serum (FBS), 1 % penicillin/streptomycin, and 1 % non-essential amino acids (all from Sigma-Aldrich Chemie, Steinheim, Germany) at 37 °C in a 5 % CO₂-enriched atmosphere with regular medium changes and passaging as needed.

Measurement of total antioxidative capacity

Total antioxidative capacity (TAC) in cell lysates was measured using the ferric reducing antioxidant power (FRAP) assay as described elsewhere (17) with slight adjustments to 96-well microplates (18, 19). The working FRAP reagent was prepared by mixing acetate buffer (300 mmol/L, pH 3.6) and a solution of 10 mmol/L tripyridyltriazine (TPTZ) in 40 mmol/L HCl and 20 mmol/L FeCl₃ in the 10:1:1 (*v/v/v*) ratio. All the chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), except for TPTZ (Fluka, Buchs, Switzerland), and FeCl₃ (Kemika, Zagreb, Croatia).

Briefly, SH-SY5Y cells were seeded at a density of 400,000 cells/well in 24-well plates. After the 4-hour treatment, we added ice-cold phosphate-buffered saline (PBS) to the wells, harvested the cells with a rubber scraper, transferred the suspension into microtubes, and sonicated them at 60 % amplitude with a UP50H ultrasonic processor (Hielscher Ultrasonics, Teltow, Germany) for half a cycle. 10 µL of the obtained cell suspension was added to 240 µL of FRAP reagent in a 96-well plate and incubated at 37 °C for 60 min. The absorbance was measured at 593 nm using a SpectraMax iD3 microplate reader (Molecular Devices, San Jose, CA, USA). TACs were calculated from the standard curve obtained from the absorbance of known Fe₂SO₄ × 7H₂O concentrations (0.02–1.0 mmol/L) and are expressed in µmol/L.

Measurement of reactive oxygen and nitrogen species

Reactive oxygen and nitrogen species (ROS and RNS, respectively) induced by the six Q(N)OHs were determined using one of the following cell-permeable reagents: 2',7'-dichlorofluorescein diacetate dye (DCFDA) or 4-amino-5-methylamino-2,7-difluorofluorescein diacetate (DAF-FM) (both from Sigma-Aldrich Chemie).

SH-SY5Y cells were seeded at a density of 20,000 cells/well in 96-well black plates. Q(N)OHs were added with either DCFDA or DAF-FM (2 µmol/L final) and pluronic acid (PA) (Sigma-Aldrich Chemie) in the final concentration of 16 µmol/L as described elsewhere in detail (20). The plate was stirred gently and immediately inserted into the plate reader (SpectraMax[®] iD3, Molecular Devices) and fluorescence registered at 495/529 nm (for DCFDA) or 485/535 nm (for DAF-FM) every 3–10 min for 4 h for ROS or for 1 h for RNS, as described in detail elsewhere (21, 22). For ROS or RNS positive controls we used hydrogen peroxide (H₂O₂) or sodium nitroprusside dihydrate (SNP) (both from Sigma-Aldrich Chemie)

in the final concentrations of 100 or 200 µmol/L, respectively. Results are expressed as normalised fluorescence signal compared to negative control.

Measurement of thiobarbituric acid reactive substances

The end products of lipid peroxidation, e.g. malondialdehyde, were measured using the thiobarbituric acid reactive substance (TBARS) following a previously described protocol (22). Briefly, SH-SY5Y cells were seeded at a density of 400,000 cells/well in 24-well plates. After the 4-h treatment, cells were harvested and sonicated as described above. 200 µL of cell suspension was added to 200 µL of thiobarbituric/trichloroacetic acid (TBA/TCA) reagent and heated to 90 °C for 30 min. Then, it was immediately cooled in an ice bath and centrifuged at 1,006 g and 4 °C for 5 min (Universal 32R centrifuge, Hettich Instruments, Beverly, MA, USA). Absorbances were measured on SpectraMax iD3 (Molecular Devices) at 532 nm.

TBARS concentrations were calculated using a standard curve constructed with 1,1,3,3-tetramethoxypropane (0.3–6.0 µmol/L) and expressed as µmol/L.

Glutathione measurement

For glutathione (GSH) measurement we used monochlorobimane (MCB, Sigma-Aldrich Chemie) as fluorescent probe and followed the protocol described elsewhere (23). *Tert*-butyl hydrogen peroxide (tBHP, Sigma-Aldrich Chemie) in the final concentration of 100 µmol/L was used as positive control. After the treatment, fluorescence was recorded on an Infinite M200PRO plate reader (Tecan Austria GmbH, Salzburg, Austria) with excitation and emission spectra of 355/460 nm. Results are expressed as normalised fluorescence signal compared to negative control.

Superoxide dismutase activity measurement

Superoxide dismutase (SOD) activity was measured using the SOD Assay Kit (Cayman Chemical, Ann Arbor, MI, USA). After the 4-h quinuclidine derivative treatment, the cells were harvested with ice-cold SOD-buffer (20 mmol/L HEPES pH 7.2, 1 mmol/L EGTA, 210 mm mannitol, 70 mmol/L sucrose), sonicated, and centrifuged at 1,500 g and 4 °C for 5 min. Supernatant was removed and centrifuged one more time at 10,000 g and 4 °C for 15 min. Supernatant was then removed for the assay (Cu/Zn-SOD), while the pellet was resuspended in SOD buffer (Mn-SOD). Samples and standards, 10 µL/well, were mixed in a transparent 96-well plate with 200 µL of diluted radical detector and 20 µL diluted xanthine oxidase from the kit and incubated in a shaker at 22–24 °C for 30 min. Absorbance was recorded on an Infinite M200PRO (Tecan Austria) plate reader at 450 nm. The final concentration of 100 µmol/L of tBHP (Sigma-Aldrich Chemie) was used as positive control.

Results are expressed as SOD activity normalised to protein concentration (U/mg of protein). Protein concentrations were

measured using the biochonic acid (BCA) assay (Pierce™ BCA Protein Assay Kit, Thermo Fisher Scientific, Waltham, MA, USA) as described elsewhere (21). Absorbance was detected on a plate reader at 570 nm.

Measurement of DNA damage

DNA damage was assessed by measuring the activation of ATM kinase and phosphorylated histone H2A.X using the Muse Multi-Color DNA Damage Kit for the Guava Muse Cell Analyzer (Luminex, Czerwostochowa, Poland). The procedure followed a previously described protocol (24) based on specific antibodies. 24-h treatment with 10 $\mu\text{mol/L}$ etoposide (Sigma-Aldrich Chemie) served as a positive control. The results are presented as percentage of total DNA damage relative to negative control.

Statistical analysis

All data were analysed from at least two or three independent experiments (performed in duplicate or triplicate). Statistical analyses was run on the Prism 9 software (GraphPad Software, San Diego, CA, USA) was used. If not otherwise stated, results are presented as means with standard errors.

Differences between the groups were tested with the one-way ANOVA, followed by Dunnett's test. Statistical significance was set to $p < 0.05$.

RESULTS

None of the quinuclidine derivative treatments resulted in significant changes in TBARS concentrations in SH-SY5Y cells compared to negative control (Figure 1), but all QNOHs significantly increased ROS and RNS levels (Figure 2). Increase in ROS depended on their side chain substituent length (Figure 2A), while in RNS it remained the same, regardless of the QNOH chain length (Figure 2B).

Total antioxidant capacity in cells treated with quinuclidine derivatives dropped compared to negative control, but not significantly (Figure 3A), whereas GSH levels dropped significantly only in cells treated with QNOH- C_{12} and QOH- C_{12} (Figure 3B).

Cytosolic SOD (Cu/Zn-SOD) activity significantly increased in SH-SY5Y cells treated with QOH- C_{16} , QNOH- C_{14} , and QNOH- C_{16} (Figure 4A). Mitochondrial SOD (Mn-SOD) activity significantly decreased with all quinuclidine derivative treatments (Figure 4B).

We found no significant DNA damage in cells treated with quinuclidine derivatives (Figure 5), which may be owed to the wide distribution of results obtained with the used method.

DISCUSSION

Our findings show varying oxidative effects relative to the structural differences between the six tested LOAEL quinuclidine

derivatives in SH-SY5Y cells. QNOH compounds induced more changes than QOH compounds. ROS and RNS levels were elevated in response to QNOH treatment, regardless of the substituent alkyl chain length, and were accompanied by changes in SOD activities and to a lesser extent in GSH levels. High levels of ROS and RNS are often connected due to shared sources (such as mitochondria and NADPH oxidases) and amplification loops (ROS amplifying RNS production *via* iNOS) (28).

Cu/Zn SOD activity rose with longer alkyl chains, while Mn-SOD activity dropped significantly with all but QNOH- C_{12} , which suggests an imbalance in the cell's oxidative stress defence system, especially within the mitochondria, where Mn-SOD is critical for homeostasis (29). This sheds more light on the possible trigger for the decrease in mitochondrial membrane potential ($\Delta\Psi\text{m}$) and on the induction of mitochondria-mediated apoptosis observed in our earlier study (14). In addition, increased cytosolic Cu/Zn SOD may reflect a defensive mechanism to neutralise ROS/RNS spilling over from stressed mitochondria into the cytosol (29). On the other hand, this increase may be owed to general oxidative stress but cannot compensate for lower Mn-SOD activity in mitochondria and the resulting mitochondrial damage.

The finding that only C_{12} derivatives led to GSH depletion suggests that the substituent alkyl chain length influences how these compounds interact with cellular defence mechanisms. Although GSH levels in SH-SY5Y cells dropped following the treatment with QOH- C_{12} and QNOH- C_{12} , a reduction in total antioxidant capacity (TAC) is evident across all samples, indicating that all tested quinuclidine derivatives increase oxidative stress and cause redox imbalance, as suggested by Micheli et al. (30) in their docetaxel study in SH-SY5Y cells.




Figure 1 Lipid peroxidation (expressed as TBARS concentrations) in SH-SY5Y cells treated with 60 $\mu\text{mol/L}$ QOH- C_{12} , 6 $\mu\text{mol/L}$ QOH- C_{14} or QOH- C_{16} , 100 $\mu\text{mol/L}$ QNOH- C_{12} , and 25 $\mu\text{mol/L}$ QNOH- C_{14} or QNOH- C_{16} for 4 h. Control – untreated cells; H_2O_2 – positive control (100 $\mu\text{mol/L}$)




Figure 2 DCFDA- or DAF-FM fluorescence (expressed as RFUs normalised to control) indicating ROS (left panel) and RNS (right panel) levels in SH-SY5Y cells treated with 60 $\mu\text{mol/L}$ QOH-C₁₂, 6 $\mu\text{mol/L}$ QOH-C₁₄ or QOH-C₁₆, 100 $\mu\text{mol/L}$ QNOH-C₁₂, and 25 $\mu\text{mol/L}$ QNOH-C₁₄ or QNOH-C₁₆ for 4 h or 1 h, respectively. ^s $p < 0.001$; * $p < 0.0001$ (Dunnett's test). Control – untreated cells; DAF-FM – 4-amino-5-methylamino-2,7-difluorofluorescein diacetate; DCFDA – 2',7'-dichlorofluorescein diacetate dye; H₂O₂ – positive control (100 $\mu\text{mol/L}$); RFU – relative fluorescence units; SNP – positive control (200 $\mu\text{mol/L}$)




Figure 3 Total antioxidative capacity (TAC, expressed as $\mu\text{mol/L}$ of Fe²⁺ equivalents, left panel) and MCB-fluorescence indicating GSH level (expressed as RFU normalised to control, right panel) in SH-SY5Y cells treated with 60 $\mu\text{mol/L}$ QOH-C₁₂, 6 $\mu\text{mol/L}$ QOH-C₁₄ or QOH-C₁₆, 100 $\mu\text{mol/L}$ QNOH-C₁₂, and 25 $\mu\text{mol/L}$ QNOH-C₁₄ or QNOH-C₁₆ for 4 h. # $p < 0.01$; * $p < 0.0001$ (Dunnett's test). Control – untreated cells; H₂O₂ or tBHP – positive controls (100 $\mu\text{mol/L}$); RFU – relative fluorescence units; SNP – positive control (200 $\mu\text{mol/L}$)




Figure 4 Cytosolic (Cu/Zn-SOD, left panel) and mitochondrial (Mn-SOD, right panel) superoxide dismutase activity (expressed as U/mg protein) in SH-SY5Y cells treated with 60 $\mu\text{mol/L}$ QOH-C₁₂, 6 $\mu\text{mol/L}$ QOH-C₁₄ or QOH-C₁₆, 100 $\mu\text{mol/L}$ QNOH-C₁₂, and 25 $\mu\text{mol/L}$ QNOH-C₁₄ or QNOH-C₁₆ for 4 h. * $p < 0.05$; # $p < 0.01$; \$ $p < 0.001$; & $p < 0.0001$ (Dunnett's test). Control – untreated cells; tBHP – positive control (100 $\mu\text{mol/L}$)

The induction of ROS/RNS in our study without lipid peroxidation (no significant changes in TBARS) suggests that ROS/RNS generation is primarily triggered by cellular signalling (e.g. peroxides) rather than the highly reactive species like hydroxyl radicals or superoxide anions that directly attack lipids (31). This is a common feature of many synthetic compounds that disrupt mitochondrial function or electron transport chains (28). Interestingly, treatment with H₂O₂ also did not induce significant lipid peroxidation in SH-SY5Y cells, suggesting that either the 100 $\mu\text{mol/L}$ concentration was insufficient to overcome cellular antioxidant defences or that additional pro-oxidant conditions (e.g., transition of metal ions) are required to trigger lipid peroxidation.

Moreover, the lack of significant DNA damage despite ROS/RNS generation suggests that the compounds may not directly cause DNA breaks. However, the potential for indirect DNA damage may still exist, as these effects are not always immediately detected, depending on experimental conditions (33, 34). As far as we know, the processes triggered in our study could end in cell death in 24 h, as some compounds induce cumulative cellular damage over time, especially through mechanisms like oxidative stress, mitochondrial dysfunction, and enzyme inhibition (35–37).

Generally, the tested quinuclidine compounds induced oxidative stress with a potential to modify key antioxidant enzyme activities by affecting the mitochondrial function. This aligns with earlier reports of mitochondrial dysfunction caused by similar classes of compound (38–40).

Judging by what we know about the tested compounds at this point, the safe dose for each needs to be lower than the LOAEL

used in this study: 60 $\mu\text{mol/L}$ for QOH-C₁₂, 6 $\mu\text{mol/L}$ for QOH-C₁₄ and QOH-C₁₆, 100 $\mu\text{mol/L}$ for QNOH-C₁₂, and 25 $\mu\text{mol/L}$ for QNOH-C₁₄ and QNOH-C₁₆. Considering that QOH-C₁₂ inhibits cholinesterase (ChE) activity in the range of 9–13 $\mu\text{mol/L}$ (14), it has potential for further development, as its LOAEL is about six times higher than its inhibition constant (K_i). Even more promising




Figure 5 DNA damage (expressed as percentage normalised to the control) in SH-SY5Y cells treated with 60 $\mu\text{mol/L}$ QOH-C₁₂, 6 $\mu\text{mol/L}$ QOH-C₁₄ or QOH-C₁₆, 100 $\mu\text{mol/L}$ QNOH-C₁₂, and 25 $\mu\text{mol/L}$ QNOH-C₁₄ or QNOH-C₁₆ for 4 h. * $p < 0.0001$ (Dunnett's test). Control – untreated cells; Etoposide – positive control (10 $\mu\text{mol/L}$)

is QNOH-C₁₂, whose ChE inhibition window of 5–14 µmol/L (14), and the 100 µmol/L LOAEL provides a nearly 10-fold safety margin. However, the inhibition potencies for QOH-C₁₄, QOH-C₁₆, QNOH-C₁₄, and QNOH-C₁₆ leave no room for further development as ChE inhibitors, as they are in the same range as their LOAEL (14).

All these findings raise questions to be addressed by further investigation, especially in terms of how chain length and functional groups on the quinuclidine core modulate oxidative stress responses and affect mitochondrial integrity.

CONCLUSION

N-alkyl quaternary quinuclidines (Q(N)OHs) in our study induced oxidative stress in SH-SY5Y cells primarily through ROS and RNS but did not cause significant lipid peroxidation or DNA damage. Although the activation of the non-enzymatic antioxidative defence system (evidenced by insignificant GSH depletion) was modest, the cellular response of the enzymatic antioxidative defence system (cytosolic Cu/Zn-SOD) was highly active, which confirms oxidative stress. Moreover, the observed decrease in mitochondrial Mn-SOD activity suggests mitochondrial dysfunction.

These findings highlight the potential of Q(N)OHs to disrupt cellular redox homeostasis, with implications for further studies on their safety and therapeutic potential, including broader cellular effects and dose optimisation.

Acknowledgements

We thank Professor Ines Primožič for providing the Q(N)OH compounds. This study was performed using the facilities and equipment funded within the European Regional Development Fund project KK.01.1.1.02.0007 “Research and Education Centre of Environmental Health and Radiation Protection – Reconstruction and Expansion of the Institute for Medical Research and Occupational Health”.

This study is part of the BioMolTox project funded by the Croatian Science Foundation (grant No. UIP-2017-05-7260) and by the European Union Next Generation Programme contract of 8 December 2023 (Class: 643-02/23-01/00016, Reg. No. 533-03-23-0006).

Conflict of interests

None to declare.

REFERENCES

1. Cammerer SB, Jimenez C, Jones S, Gros L, Lorente SO, Rodrigues C, Rodrigues JCF, Caldera A, Ruiz Perez LM, da Souza W, Kaiser M, Brun R, Urbina JA, Gonzalez Pacanowska D, Gilbert IH. Quinuclidine derivatives as potential antiparasitics. *Antimicrob Agents Chemother* 2007;51:4049–61. doi: 10.1128/AAC.00205-07
2. Bazina L, Maravić A, Krce L, Soldo B, Odžak R, Popović VB, Aviani I, Primožič I, Šprung M. Discovery of novel quaternary ammonium compounds based on quinuclidine-3-ol as new potential antimicrobial candidates. *Eur J Med Chem* 2019;163:626–35. doi: 10.1016/j.ejmech.2018.12.023
3. Skočibušić M, Odžak R, Štefanić Z, Križić I, Krišto L, Jović O, Hrenar T, Primožič I, Jurašin D. Structure–property relationship of quinuclidinium surfactants—Towards multifunctional biologically active molecules. *Colloids Surfaces B Biointerfaces* 2016;140:548–59. doi: 10.1016/j.colsurfb.2015.11.023
4. Zandona A, Katalinić M, Šinko G, Radman Kastelic A, Primožič I, Kovarik Z. Targeting organophosphorus compounds poisoning by novel quinuclidine-3 oximes: development of butyrylcholinesterase-based bioscavengers. *Arch Toxicol* 2020;94:3157–71. doi: 10.1007/s00204-020-02811-5
5. Fernandes AR, Sanchez-Lopez E, Santini A, Santos T dos, Garcia ML, Silva AM, Souto EB. Mono- and dicationic DABCO/quinuclidine composed nanomaterials for the loading of steroidal drug: 32 factorial design and physicochemical characterization. *Nanomaterials* 2021;11(10):2758. doi: 10.3390/nano11102758
6. Zakharova LY, Pashirova TN, Doktorovova S, Fernandes AR, Sanchez-Lopez E, Silva AM, Souto SB, Souto EB. Cationic surfactants: Self-assembly, structure-activity correlation and their biological applications. *Int J Mol Sci* 2019;20(22):5534. doi: 10.3390/ijms20225534
7. Hamama WS, El-Magid OMA, Zoorob HH. Chemistry of quinuclidines as nitrogen bicyclic bridged-ring structures. *J Heterocycl Chem* 2006;43:1397–420. doi: 10.1002/jhet.5570430601
8. Yakhontov LN. Quinuclidine chemistry. *Adv Heterocycl Chem* 1970;11:473–523. doi: 10.1016/S0065-2725(08)60778-3
9. Odžak R. Biological activity of monoquaternary ammonium compounds based on 3-substituted quinuclidine: A short review. *Period Biol* 2020;121–122:15–21. doi: 10.18054/pb.v121-122i1-2.10603
10. Reiner E, Škrinjaric Špoljar M, Dunaj S, Simeon-Rudolf V, Primožič I, Tomić S. 3-Hydroxyquinuclidinium derivatives: synthesis of compounds and inhibition of acetylcholinesterase. *Chem Biol Interact* 1999;119–120:173–81. doi: 10.1016/S0009-2797(99)00026-5
11. Katalinić M, Zandona A, Ramić A, Zorbaz T, Primožič I, Kovarik Z. New cinchona oximes evaluated as reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by organophosphorus compounds. *Molecules* 2017;22(7):1234. doi: 10.3390/molecules22071234
12. Matošević A, Radman Kastelic A, Mikelić A, Zandona A, Katalinić M, Primožič I, Bosak A, Hrenar T. Quinuclidine-based carbamates as potential CNS active compounds. *Pharmaceutics* 2021;13(3):420. doi: 10.3390/pharmaceutics13030420
13. Lulić A-M, Marčelić L, Ramić A, Kastelic AR, Zandona A, Maraković N, Primožič I, Katalinić M. Cholinesterase activity modulators: Evaluation of dodecylaminoquinuclidines as inhibitors of human AChE and BChE. *Chem Biol Interact* 2025;417:111567. doi: 10.1016/j.cbi.2025.111567
14. Žunec S, Vadjla D, Ramić A, Zandona A, Maraković N, Brekalo I, Primožič I, Katalinić M. Profiling novel quinuclidine-based derivatives as potential anticholinesterase drugs: Enzyme inhibition and effects on cell viability. *Int J Mol Sci* 2024;25(1):155. doi: 10.3390/ijms25010155
15. Walczak-Nowicka ŁJ, Herbet M. Acetylcholinesterase inhibitors in the treatment of neurodegenerative diseases and the role of

- acetylcholinesterase in their pathogenesis. *Int J Mol Sci* 2021;22(17):9290. doi: 10.3390/ijms22179290
16. Radman Kastelic A, Odžak R, Pezdirc I, Sović K, Hrenar T, Čipak Gašparović A, Skočibušić M, Primožič I. New and potent quinuclidine-based antimicrobial agents. *Molecules* 2019;24(14):2675. doi: 10.3390/molecules24142675
 17. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay. *Anal Biochem* 1996;239:70–6. doi: 10.1006/abio.1996.0292
 18. Kozics K, Klusová V, Srančíková A, Mučaji P, Slameňová D, Hunáková E, Kusznierevich B, Horváthová E. Effects of *Salvia officinalis* and *Thymus vulgaris* on oxidant-induced DNA damage and antioxidant status in HepG2 cells. *Food Chem* 2013;141:2198–206. doi: 10.1016/j.foodchem.2013.04.089
 19. Jalili-Baleh L, Nadri H, Forootanfar H, Küçükkinç TT, Ayazgök B, Sharifzadeh M, Rahimifard M, Baeri M, Abdollahi M, Foroumadi A, Khoobi M. Chromone–lipoic acid conjugate: Neuroprotective agent having acceptable butyrylcholinesterase inhibition, antioxidant and copper-chelation activities. *DARU J Pharm Sci* 2021;29:23–38. doi: 10.1007/s40199-020-00378-1
 20. Barna L, Walter FR, Harazin A, Bocsik A, Kincses A, Tubak V, Jósavay K, Zvara Á, Campos-Bedolla P, Deli MA. Simvastatin, edaravone and dexamethasone protect against kainate-induced brain endothelial cell damage. *Fluids Barriers CNS* 2020;17(1):5. doi: 10.1186/s12987-019-0166-1
 21. Zandona A, Szczesko A, Žunec S, Jovanović IN, Bušić V, Sokač DG, Deli MA, Katalinić M, Veszelka S. Nicotinamide derivatives protect the blood-brain barrier against oxidative stress. *Biomed Pharmacother* 2025;186:118018. doi: 10.1016/j.biopha.2025.118018
 22. Žunec S, Kašuba V, Pavičić I, Marjanović AM, Tariba B, Milić M, Kopjar N, Pizent A, Vrdoljak AL, Rozgaj R, Želježić D. Assessment of oxidative stress responses and the cytotoxic and genotoxic potential of the herbicide tembotrione in HepG2 cells. *Food Chem Toxicol* 2016;94:64–74. doi: 10.1016/j.fct.2016.05.019
 23. Zandona A, Maraković N, Mišetić P, Madunić J, Miš K, Padovan J, Pirkmajer S, Katalinić M. Activation of (un)regulated cell death as a new perspective for bispyridinium and imidazolium oximes. *Arch Toxicol* 2021;95:2737–54. doi: 10.1007/s00204-021-03098-w
 24. Zandona A, Madunić J, Miš K, Maraković N, Dubois-Geoffroy P, Cavaco M, Mišetić P, Padovan J, Castanho M, Jean L, Renard P-Y, Pirkmajer S, Neves V, Katalinić M. Biological response and cell death signaling pathways modulated by tetrahydroisoquinoline-based aldoximes in human cells. *Toxicology* 2023;494:153588. doi: 10.1016/j.tox.2023.153588
 25. Emilen G, van Meurs W, Maloteaux JM. The dose-response relationship in Phase I clinical trials and beyond use, meaning, and assessment. *Pharmacol Ther* 2000;88:33–58. doi: 10.1016/S0163-7258(00)00077-2
 26. Hartwig A, Arand M, Epe B, Guth S, Jahnke G, Lampen A, Martus H-J, Monien B, Rietjens IMCM, Schmitz-Spanke S, Schriever-Schwemmer G, Steinberg P, Eisenbrand G. Mode of action-based risk assessment of genotoxic carcinogens. *Arch Toxicol* 2020;94:1787–877. doi: 10.1007/s00204-020-02733-2
 27. Borgert CJ, Fuentes C, Burgoon LD. Principles of dose-setting in toxicology studies: the importance of kinetics for ensuring human safety. *Arch Toxicol* 2021;95:3651–64. doi: 10.1007/s00204-021-03155-4
 28. Di Meo S, Reed TT, Venditti P, Victor VM. Role of ROS and RNS sources in physiological and pathological conditions. *Oxid Med Cell Longev* 2016;2016:1245049. doi: 10.1155/2016/1245049
 29. Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. *J Cell Biol* 2018;217:1915–28. doi: 10.1083/jcb.201708007
 30. Micheli L, Collodel G, Moretti E, Noto D, Menchiari A, Cerretani D, Crispino S, Signorini C. Redox imbalance induced by docetaxel in the neuroblastoma SH-SY5Y cells: a study of docetaxel-induced neuronal damage. *Redox Rep* 2021;26:18–28. doi: 10.1080/13510002.2021.1884802
 31. Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. *Oxid Med Cell Longev* 2014;2014:360438. doi: 10.1155/2014/360438
 32. Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. *Redox Biol* 2019;25:101084. doi: 10.1016/j.redox.2018.101084
 33. Sharma V, Collins LB, Chen T, Herr N, Takeda S, Sun W, Swenberg JA, Nakamura J. Oxidative stress at low levels can induce clustered DNA lesions leading to NHEJ mediated mutations. *Oncotarget* 2016;7:25377–90. doi: 10.18632/oncotarget.8298
 34. Giorgio M, Dellino GI, Gambino V, Roda N, Pellicci PG. On the epigenetic role of guanosine oxidation. *Redox Biol* 2020;29:101398. doi: 10.1016/j.redox.2019.101398
 35. Miller MA, Zachary JF. Mechanisms and morphology of cellular injury, adaptation, and death. *Pathol Basis Vet Dis* 2017;2–43.e19. doi: 10.1016/B978-0-323-35775-3.00001-1
 36. Timbrell JA. Principles of Biochemical Toxicology. 3rd ed. London: CRC Press; 1999. doi: 10.1201/9781003004301
 37. Kowalczyk P, Sulejczak D, Kleczkowska P, Bukowska-Ośko I, Kucia M, Popiel M, Wietrak E, Kramkowski K, Wrzosek K, Kaczyńska K. Mitochondrial oxidative stress – A causative factor and therapeutic target in many diseases. *Int J Mol Sci* 2021;22(24):13384. doi: 10.3390/ijms222413384
 38. Liao X, Han Y, He Y, Liu J, Wang Y. Natural compounds targeting mitochondrial dysfunction: emerging therapeutics for target organ damage in hypertension. *Front Pharmacol* 2023;14:1209890. doi: 10.3389/fphar.2023.1209890
 39. Zong Y, Li H, Liao P, Chen L, Pan Y, Zheng Y, Zhang C, Liu D, Zheng M, Gao J. Mitochondrial dysfunction: mechanisms and advances in therapy. *Signal Transduct Target Ther* 2024;9(1):124. doi: 10.1038/s41392-024-01839-8
 40. Reddam A, McLarnan S, Kupsco A. Environmental chemical exposures and mitochondrial dysfunction: A review of recent literature. *Curr Environ Heal Reports* 2022;9:631–49. doi: 10.1007/s40572-022-00371-7

Učinci *N*-alkil kvaternih kinuklidina na biomarkere oksidacijskog stresa u stanicama SH-SY5Y

Zbog širokog spektra bioloških i farmakoloških aktivnosti, uključujući antikolinergičko, antihistaminsko, antiparazitsko, antioksidacijsko i antitumorsko djelovanje, derivati kinuklidina izazvali su velik interes u području razvoja novih lijekova i biomedicinskih istraživanja. U ovom su istraživanju analizirani učinci oksidacijskog stresa šest *N*-alkil kvaternih derivata kinuklidina – tri oksima (QNOH- $C_{12^{*}14^{*}16^{*}}$) i tri alkohola (QOH- $C_{12^{*}14^{*}16^{*}}$) – u stanicama neuroblastoma SH-SY5Y kako bi se procijenio njihov sigurnosni profil kao potencijalnih terapeutika. Stanice SH-SY5Y tretirane su najnižim koncentracijama koje prouzrokuju štetni učinak (LOAEL) tijekom 4 sata, nakon čega su izmjerene razine reaktivnih kisikovih i dušikovih vrsta (ROS i RNS), peroksidacije lipida, glutaciona (GSH), aktivnosti superoksid dismutaze (SOD) i oštećenja DNA. Spojevi Q(N)OH značajno su povećali razine ROS i RNS, osobito QNOH spojevi; peroksidacija lipida nije bila potaknuta, a smanjenje razine GSH bilo je minimalno. Aktivnost citosolnoga Cu/Zn-SOD značajno je rasla s duljinom alkilnoga lanca, dok je aktivnost mitohondrijskoga Mn-SOD opadala, što upućuje na oštećenje mitohondrija. Nije zabilježeno povećanje oštećenja DNA. Uočeni učinci testiranih kinuklidinskih derivata ovise o njihovim strukturnim svojstvima, pri čemu su spojevi s hidroksilnim skupinama i kraćim alkilnim lancima pokazali manji utjecaj. Stoviše, čak su i necitotoksične doze ispitivanih spojeva narušile staničnu homeostazu, što naglašava važnost ovakva testiranja u ranoj fazi procjene sigurnosti novih potencijalnih lijekova.

KLJUČNE RIJEČI: glutation; mitohondrijska disfunkcija; oksimi; oštećenje DNA; reaktivne dušikove vrste; reaktivne kisikove vrste; superoksid-dismutaza